Imatinib is a selective tyrosine kinase inhibitor which acts on breakpoint cluster region-Abelson fusion gene (BCR-ABL) positive leukemia including all phases of chronic myeloid leukemia and acute lymphoblastic leukemia. It may induce rapid apoptosis and subsequent tumor lysis syndrome. Only 3 cases of imatinib-induced tumor lysis syndrome have been reported. We herein described an additional p...

  A male patient with acute renal failure (ARF) due to large B-cell non-Hodgkin lymphoma infiltration of kidney is presented. The diagnosis was suspected because of coincidence of ARF and tumor lysis syndrome non-responsive to conservative renal therapies. A renal biopsy confirmed diagnosis and appropriate chemotherapy led to complete improvement of renal function.  

TLS (tumor lysis syndrome) is a serious consequence of haematologic malignancies and their treatment. The condition defined by laboratory abnormalities alone (laboratory TLS) or in conjunction with clinical consequences such as renal failure, seizures, arrhythmias (clinical TLS). Clinical risk factor for increased morbidity death cancer patients, although it may be avoided. As result, accurate ...

Tumor lysis syndrome has been observed in patients with bulky, treatment-sensitive tumors, in particular hematological malignancies, especially after medical treatment (chemotherapy, corticosteroids, radiation, hormonal agents, and biological response modifiers). Tumor lysis syndrome has been observed also in solid malignancies and it very rarely occurs spontaneously. Tumor lysis syndrome-assoc...